Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:HOND News 15 October 2025 - 20 October 2025

Nuclear SPAC Stock Skyrockets: Terrestrial Energy’s SPAC Deal Ignites Investor Frenzy

Nuclear SPAC Stock Skyrockets: Terrestrial Energy’s SPAC Deal Ignites Investor Frenzy

Terrestrial Energy is a Generation-IV nuclear developer known for its IMSR technology ts2.tech businesswire.com. The IMSR is a modular molten-salt reactor that uses low-enriched uranium; it is inherently safe thanks to its fuel salt and temperature control design ts2.tech globenewswire.com. Terrestrial has been building regulatory momentum: besides the recent NRC ruling, Canada’s regulator completed a positive Vendor Design Review in 2023, finding “no fundamental barriers to licensing” the IMSR for commercial use globenewswire.com. The company plans to build first IMSR plants in the early 2030s and markets them not only for electricity but also high-temperature industrial heat (data centers, chemical
20 October 2025
·····
Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears

Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears

HOND stock has surged into the mid-$20s (around $24.98 as of Oct. 15, 2025) after trading in the high teens last week Investing Marketbeat. Its volume spiked (about 1.14 million shares on Oct. 13) and the stock gapped up from $18.86 to $21.69 at open on Oct. 13 Marketbeat. – The catalyst is a proposed merger with Terrestrial Energy Inc., a next-gen nuclear reactor company. The SEC declared the merger’s S-4 registration effective on Sept. 26, and HCM II shareholders will vote on Oct. 20 to approve the deal Businesswire Businesswire. If approved, the combined firm will list on Nasdaq
15 October 2025
····

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
BAT share price closes near 52-week high as buyback rolls on ahead of results week

BAT share price closes near 52-week high as buyback rolls on ahead of results week

7 February 2026
British American Tobacco shares closed up 1.2% at 4,609 pence Friday, near a 52-week high. The company disclosed further share buybacks and management share purchases ahead of its Feb. 12 full-year results. BAT bought 121,668 shares for cancellation on Feb. 5. Investors await updates on nicotine alternatives and cash returns.
Anglo American share price slips as BofA turns neutral after copper outlook cut

Anglo American share price slips as BofA turns neutral after copper outlook cut

7 February 2026
Anglo American shares closed down 0.75% at 3,435 pence Friday after BofA Global Research downgraded the miner to “neutral” and raised its price target to 3,600 pence. Anglo cut its 2026 copper production guidance and warned of continued weakness at De Beers. The company expects $200 million in charges tied to its Chile copper operations in the second half of 2025.
Go toTop